Abstract 347P
Background
In this study, we summarize the chemokines that are involved in malignant HTLV-1 associated disease, adult T cell leukemia/lymphoma (ATLL) progression. The interaction of virus and host were evaluated in chemokine level.
Methods
The expression of CCR6, CXCR-3, the HTLV-1 proviral load (PVL), HTLV-1-Tax, and HBZ were assessed in 12 asymptomatic HTLV-1carriers (ACs), 12 healthy controls (HCs) and 12 ATLL patients. We applied quantitative real-time PCR (qRT-PCR) and TaqMan method.
Results
As per results, the level of CXCR3 gene expression in ATLL patients compared to HTLV-1 virus carriers and healthy people showed a significant difference (P=0.00 and P=0.008). Also, the mean expression of CCR6 genes in ATLL patients compared to HTLV-1 virus carriers had a significant difference of P=0.04, but in the ATLL group there was no significant difference compared to the healthy group.
Conclusions
Our study results illustrate that the expression of chemokine receptors is directly related to the course and stages of the disease as well as the prognosis of the disease. In carriers, compared to healthy individuals, we still have a higher level of expression of chemokine. In addition, with the progression of the conflict and the progression to malignancy and involvement of T lymphocytes (the producer of these chemokines) as shown in our study, we can conclude that with decreased levels of these chemokine receptors can lead to malignancy with a poor prognosis. Our findings confirm previous studies that Tax protein may not be expressed in ATLL patients. Additionally, an oncoprotein may involve in inducing malignancy, but in the absence of Tax, HTLV-1-HBZ protein implicated in the maintenance of mechanism of the virus to escape from the host cell immune system. We also found an increase in virus load as HTLV-1 carriers move toward. So these chemokines could be suggested as influential targets for the prognosis and proper therapy of ATLL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract